RxSight, Inc. (NASDAQ:RXST) Shares Bought by RiverPark Advisors LLC

RiverPark Advisors LLC increased its holdings in RxSight, Inc. (NASDAQ:RXST) by 361.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,082 shares of the company’s stock after purchasing an additional 2,414 shares during the quarter. RiverPark Advisors LLC’s holdings in RxSight were worth $159,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Capstone Investment Advisors LLC acquired a new position in RxSight in the 4th quarter worth about $642,000. Principal Financial Group Inc. raised its holdings in RxSight by 298.5% in the 1st quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock worth $1,802,000 after purchasing an additional 26,164 shares during the period. Victory Capital Management Inc. increased its stake in RxSight by 108.6% during the 4th quarter. Victory Capital Management Inc. now owns 256,684 shares of the company’s stock worth $10,349,000 after buying an additional 133,642 shares in the last quarter. Parkman Healthcare Partners LLC increased its stake in RxSight by 34.5% during the 4th quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock worth $20,685,000 after buying an additional 131,701 shares in the last quarter. Finally, Seven Eight Capital LP purchased a new stake in RxSight during the 4th quarter worth approximately $1,085,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on RXST. Stifel Nicolaus boosted their price objective on RxSight from $64.00 to $68.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. BTIG Research boosted their price objective on RxSight from $61.00 to $72.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC upped their price target on RxSight from $64.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Wells Fargo & Company upped their price target on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. Finally, Oppenheimer upped their price target on RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, May 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight presently has an average rating of “Buy” and an average price target of $64.71.

RxSight Trading Up 0.1 %

RxSight stock traded up $0.04 during mid-day trading on Tuesday, hitting $56.99. The company’s stock had a trading volume of 308,090 shares, compared to its average volume of 436,191. The firm has a market capitalization of $2.11 billion, a PE ratio of -45.23 and a beta of 1.20. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54. The stock’s fifty day moving average is $58.99 and its two-hundred day moving average is $52.86.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.08). The business had revenue of $29.51 million during the quarter, compared to analysts’ expectations of $27.56 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The company’s revenue was up 68.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.42) earnings per share. On average, equities analysts expect that RxSight, Inc. will post -0.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ronald M. Md Kurtz sold 40,000 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $60.15, for a total value of $2,406,000.00. Following the completion of the transaction, the chief executive officer now directly owns 764,610 shares in the company, valued at $45,991,291.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other RxSight news, CEO Ronald M. Md Kurtz sold 40,000 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the transaction, the chief executive officer now directly owns 764,610 shares in the company, valued at $45,991,291.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total value of $526,900.00. Following the transaction, the chief financial officer now owns 13,938 shares in the company, valued at $734,393.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,625 shares of company stock worth $4,425,250. Company insiders own 9.36% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.